Ziconotide (Prialt): Complete Research Profile — FDA-Approved Conopeptide N-Type Calcium Channel Blocker for Pain Research (2026)

# Ziconotide (Prialt): Complete Research Profile — FDA-Approved Conopeptide N-Type Calcium Channel Blocker for Pain Research (2026)

Ziconotide — marketed as Prialt — occupies a singular position in both clinical medicine and pharmacological research. It is the only FDA-approved non-opioid intrathecal analgesic, the only drug derived from cone snail venom to reach clinical practice, and one of the most selective blockers of N-type voltage-gated calcium channels (Cav2.2/CACNA1B) known to science. Since its 2004 approval for severe chronic pain refractory to opioids, ziconotide has served as both a last-resort pain therapy and an indispensable tool for dissecting calcium channel biology in nociceptive circuits.

This profile covers ziconotide's molecular origin, mechanism, clinical pharmacology, research applications, and the key scientific questions it continues to help answer.

> Research Use Only (RUO) Notice: This article is for educational and scientific purposes only. Ziconotide is an FDA-approved prescription pharmaceutical (NDA 021060) administered exclusively via intrathecal infusion under medical supervision. Any laboratory use of ziconotide or its analogs must comply with applicable regulations. This content does not constitute medical advice.

---

Molecular Origin: From Cone Snail Venom to Synthetic Peptide

Ziconotide is the synthetic equivalent of ω-conotoxin MVIIA (also written ω-CTx-MVIIA), a naturally occurring peptide toxin isolated from the venom of Conus magus — the "magician's cone snail" found in the Indo-Pacific. The venom of Conus species is a molecular armory: each snail produces hundreds of unique conopeptides (conotoxins) that target ion channels, receptors, and transporters with extraordinary selectivity to rapidly immobilize prey.

Structural Characteristics

Ziconotide is a 25-amino acid peptide with the sequence:

CKGKGAKCSRLMYDCCTGSCRSGKC-NH₂

Key structural features:

• •Three disulfide bridges forming the "ICK" (inhibitor cystine knot) scaffold — a motif shared across many venom peptides that confers protease resistance and conformational rigidity
• •C-terminal amidation (-NH₂), common among bioactive neuropeptides and required for full pharmacological activity
• •Molecular weight: ~2,639 Da
• •Disulfide connectivity: C1-C16, C8-C20, C15-C25 — the canonical ω-conotoxin arrangement

This compact, heavily cross-linked architecture gives ziconotide exceptional stability in aqueous solution compared to linear peptides, though it still requires refrigeration and is incompatible with many standard formulations.

Why Synthetic?

The naturally occurring ω-conotoxin MVIIA cannot be harvested in sufficient quantities from Conus magus for pharmaceutical use. Total chemical synthesis (via solid-phase peptide synthesis, SPPS) followed by oxidative refolding to achieve correct disulfide pairing is the manufacturing route for ziconotide. Synthetic production also enables isotopic labeling, structure-activity relationship (SAR) studies, and analog design in research settings.

---

Mechanism of Action: Selective Cav2.2 N-Type Calcium Channel Blockade

Understanding ziconotide's mechanism requires understanding the role of N-type calcium channels in pain transmission.

N-Type Calcium Channels (Cav2.2) in Nociception

Voltage-gated calcium channels (VGCCs) are divided into subfamilies based on their pharmacology and α₁ subunit gene (CACNA1A through CACNA1H). Cav2.2 channels, encoded by CACNA1B, are:

• •Predominantly expressed on presynaptic terminals of nociceptive (pain-sensing) primary afferent neurons (C-fibers and Aδ-fibers)
• •Located in the dorsal horn of the spinal cord, where primary afferents synapse onto second-order neurons in the spinothalamic tract
• •Activated by membrane depolarization following noxious stimuli, triggering Ca²⁺ influx that drives neurotransmitter release

When a pain signal travels along a C-fiber to the dorsal horn, action potential propagation depolarizes presynaptic terminals and opens Cav2.2 channels. The resulting Ca²⁺ influx triggers vesicular fusion and the release of pain neurotransmitters — primarily glutamate and substance P — onto second-order neurons in laminae I and II.

Ziconotide's Binding Site and Pharmacodynamics

Ziconotide binds with high affinity (Ki ≈ 0.1–0.5 nM) to the outer vestibule of the Cav2.2 channel pore, physically occluding Ca²⁺ entry. Key features of this blockade:

By blocking presynaptic Ca²⁺ influx, ziconotide prevents the release of glutamate and substance P at dorsal horn synapses, interrupting nociceptive transmission upstream of the first synapse — a mechanistically distinct site from opioid receptors.

No Tolerance Development

One of ziconotide's most clinically and scientifically important properties is the absence of tolerance. Opioid tolerance arises from receptor desensitization, internalization, and downstream signaling adaptations. Because ziconotide acts on an ion channel rather than a G-protein-coupled receptor, these adaptive mechanisms do not apply. Long-term intrathecal use (months to years) does not require dose escalation to maintain analgesia — a finding with significant implications for understanding chronic pain pharmacology.

---

FDA Approval and Clinical Context

Approval History

The FDA approved ziconotide (Prialt, Jazz Pharmaceuticals) on December 28, 2004 (NDA 021060) for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatments (opioids, adjuvants).

This approval followed pivotal Phase III trials demonstrating statistically significant pain reduction on the Visual Analog Scale (VASPI) compared to placebo in patients with cancer pain, HIV-related pain, and non-malignant neuropathic pain.

Delivery System

Ziconotide can only be administered via intrathecal infusion — delivered directly into the cerebrospinal fluid (CSF) through an implanted intrathecal drug delivery system (IDDS, e.g., Medtronic SynchroMed II pump). This route is necessitated by the peptide's inability to cross the blood-brain barrier (BBB) at systemic doses and its rapid degradation in plasma.

Therapeutic Window and Safety Profile

Ziconotide has a narrow therapeutic window, which distinguishes it from most analgesics. The therapeutic dose range sits close to the dose producing neurological adverse effects:

• •CNS effects at supratherapeutic levels: Dizziness, nystagmus, ataxia, confusion, somnolence, hallucinations, psychosis (the latter requiring immediate drug discontinuation)
• •No respiratory depression — a critical advantage over opioids in this patient population
• •No physical dependence — abrupt discontinuation does not cause withdrawal syndrome
• •Psychiatric monitoring required throughout treatment due to rare but serious CNS adverse effects

The narrow window and psychiatric risk profile make ziconotide a specialist drug, but its lack of respiratory depression and addiction potential represents a genuine clinical advance for appropriate patients.

Position Among Intrathecal Analgesics

Ziconotide is compared against two other primary intrathecal agents:

Ziconotide is typically considered after inadequate response to intrathecal opioids, or as a first-line option when opioid tolerance or respiratory compromise is a concern.

---

Research Applications

1. Pain Neuroscience: Dissecting Nociceptive Circuits

Ziconotide and ω-conotoxin MVIIA are indispensable pharmacological tools for establishing the contribution of Cav2.2 to specific pain modalities and circuits. Classic experiments using intrathecal or local ziconotide application have demonstrated:

• •N-type channels mediate spinal sensitization (wind-up) following repetitive C-fiber stimulation
• •Cav2.2 expression is upregulated in dorsal root ganglia (DRG) neurons following peripheral nerve injury, contributing to neuropathic pain hypersensitivity
• •Cav2.2 trafficking to presynaptic terminals is regulated by the CRMP-2 (collapsing response mediator protein-2) protein — a druggable interaction for novel analgesic development

2. N-Type Calcium Channel Characterization

In patch-clamp electrophysiology, ω-conotoxin MVIIA / ziconotide is the gold-standard pharmacological tool for isolating Cav2.2 current components:

• •Applied extracellularly to block Cav2.2, allowing subtraction of Cav2.2-specific current from total Ca²⁺ current
• •Used alongside ω-agatoxin IVA (Cav2.1 blocker) and nifedipine (Cav1.x blocker) to achieve complete Ca²⁺ current pharmacological dissection
• •Enables study of Cav2.2 kinetics, gating, and modulation by auxiliary subunits (α₂δ, β, γ subunits) independently

3. Conotoxin Scaffold Studies and Drug Discovery

The ICK scaffold of ziconotide serves as a template for engineering next-generation analgesics:

• •Cyclization strategies: Head-to-tail cyclic analogs and disulfide-deleted variants are being explored for improved BBB permeability and oral bioavailability
• •Subtype selectivity engineering: Mutagenesis of key contact residues (Tyr13, Lys2, Arg10 in MVIIA) to discriminate Cav2.2 from closely related Cav2.1 and Cav2.3
• •Hybrid peptides: Fusion of the Cav2.2-binding pharmacophore with cell-penetrating peptides (CPPs) to enable systemic delivery

4. Intrathecal Drug Delivery Research

The clinical use of ziconotide has driven substantial research into intrathecal delivery systems:

• •Stability studies: Ziconotide is incompatible with certain catheter materials and requires specific formulation conditions (pH 4.0–7.0, avoiding polysulfone and certain plasticizers)
• •Drug combination models: Investigation of ziconotide + morphine (IDDS combination) in animal models, seeking additive or synergistic analgesia
• •CSF pharmacokinetics: Ziconotide distributes primarily in CSF with minimal plasma levels, making it a model compound for intrathecal PK studies

5. Calcium Signaling in Dorsal Horn Neurons

Research using Ca²⁺ imaging (fura-2, GCaMP) in spinal cord slice preparations employs ziconotide to:

• •Quantify the fraction of stimulus-evoked Ca²⁺ transients that are Cav2.2-dependent
• •Examine plasticity of Ca²⁺ signaling following chronic pain states
• •Validate Cav2.2 as a target in specific laminar populations (substantia gelatinosa vs. deep dorsal horn)

---

Comparison with Other Conotoxins

Ziconotide is classified within the ω-conotoxin family (targets VGCCs), distinguishable from other major conotoxin classes by pharmacological target:

Within the ω-family, ω-conotoxin GVIA (from Conus geographus) also blocks Cav2.2 with very high affinity but binds more irreversibly and with some Cav2.3 activity — making MVIIA/ziconotide preferred for in vivo pharmacology requiring reversibility or cleaner selectivity.

---

Laboratory Protocols and Handling

Reconstitution

Ziconotide (research grade, synthetic ω-conotoxin MVIIA) is typically supplied as lyophilized powder. For laboratory use:

1. Reconstitute in sterile 0.9% saline or PBS (pH 6.5–7.4)

2. Avoid glass vials with certain surface treatments — adsorption can reduce apparent concentration; use low-binding polypropylene tubes

3. Working stock: 1 mM in sterile saline; dilute to working concentration (typically 0.1–1 μM for in vitro electrophysiology) in aCSF or extracellular solution

4. Storage: −20°C, avoid freeze-thaw cycles; add 0.1% BSA to minimize adsorption at very low concentrations

For additional reconstitution guidance, see our guide on how to reconstitute peptides.

Typical In Vitro Concentrations

---

Current Research Frontiers

Systemic Delivery Strategies

The requirement for intrathecal delivery represents a major limitation. Active research areas include:

• •CPP-conjugated ziconotide analogs capable of crossing the BBB
• •Nanoparticle encapsulation for intrathecal depot formulations with extended release
• •Truncated ziconotide analogs (MVIIA[7-25] and related fragments) with reduced size that might allow alternative routes

CRMP-2 as an Indirect Cav2.2 Target

Collapsin response mediator protein 2 (CRMP-2) interacts with the Cav2.2 intracellular domain to regulate surface trafficking. Small molecules and peptides disrupting this interaction (e.g., LBT-3627, compound 194) reduce Cav2.2 membrane density without direct channel block — offering a parallel therapeutic strategy with potentially wider therapeutic window.

Role in Neuroinflammatory Pain

Emerging data suggest that Cav2.2 on glial cells (astrocytes, microglia) also contributes to neuroinflammatory pain states. Ziconotide's primarily neuronal selectivity means these non-neuronal contributions may not be fully captured in standard experimental designs — an active area of investigation.

---

Summary for Researchers

---

Frequently Asked Questions

Is ziconotide the same as ω-conotoxin MVIIA?

Yes. Ziconotide is the INN (International Nonproprietary Name) for the synthetic version of ω-conotoxin MVIIA. The sequences are identical; the distinction is purely between naturally occurring peptide and synthetic pharmaceutical/research reagent.

Why is intrathecal delivery required?

Ziconotide is a 25-amino acid peptide that cannot cross the blood-brain barrier in pharmacologically relevant quantities following systemic administration. Additionally, systemic doses high enough to achieve CNS effect would cause severe peripheral cardiovascular effects. Intrathecal delivery targets the drug precisely to CSF surrounding the spinal cord.

Does ziconotide interact with opioid receptors?

No. Ziconotide has no affinity for μ-, δ-, or κ-opioid receptors. It is pharmacologically and mechanistically distinct from all opioid analgesics, which is why it can provide analgesia in opioid-tolerant patients.

What makes Cav2.2 a better pain target than Cav2.1 or Cav1.x?

Cav2.2 is selectively enriched at spinal nociceptive synapses, while Cav2.1 (P/Q-type) predominates at cerebellar synapses and neuromuscular junctions, and Cav1.x (L-type) predominates in muscle and endocrine tissues. Selective Cav2.2 blockade achieves spinal analgesia without the motor or cardiac effects of non-selective calcium channel blockers.

---

This article is intended for educational and research purposes only. Ziconotide (Prialt) is a Schedule II-equivalent prescription pharmaceutical requiring specialized administration. All laboratory use of research-grade ziconotide analogs must comply with applicable institutional and regulatory requirements.